HBM HOLDINGS-B(02142): The phase II SIRIUS study of HBM9378/WIN378, a fully human long-acting targeted TSLP antibody for treating COPD, has completed dosing of the first batch of patients.

HBM HOLDINGS-B (02142) announced that the company's partner, Windward Bio AG (Windward Bio), has completed dosing the first group of patients in the II phase SIRIUS study for the treatment of chronic obstructive pulmonary disease (COPD) with HBM9378/WIN378 (also known as SKB378, a fully human long-acting antibody targeting thymic stromal lymphopoietin (TSLP)). SIRIUS is a global phase II randomized, double-blind, placebo-controlled, dose-exploration study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of HBM9378/WIN378 in patients with moderate to severe COPD. HBM9378/WIN378 is also currently being evaluated in Windward Bio's phase II/III POLARIS asthma study, with preliminary phase II data expected in the second half of 2026. Windward Bio anticipates that the first phase III study for asthma with HBM9378/WIN378 will commence in the fourth quarter of 2026. The initiation of the SIRIUS COPD study expands the clinical development of HBM9378/WIN378 to COPD as a second major respiratory disease. The board of directors believes that the initiation of the SIRIUS COPD study marks continued clinical progress for HBM9378/WIN378, further supporting the potential of this molecule as a differentiated, long-acting targeted TSLP antibody for the treatment of immune-related diseases.